C4X Discovery CEO, Clive Dix, receives OBN Special Recognition Award 2021


C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

26 November 2021

C4X Discovery Holdings plc (AIM: C4XD), is honoured to announce that CEO, Dr Clive Dix has received the Special Recognition Award at the OBN 2021 Awards for his life-long contribution to the UK life sciences industry.

Eva-Lotta Allan, Chairman of C4X Discovery, commented:
“The prestigious OBN Awards celebrate the very best of UK life science.  We are therefore very proud of all that Clive has achieved throughout his career, and in particular, here at C4XD. 

Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive.  He has the scientific expertise, industry experience and leadership qualities that are needed to grow companies in such a challenging industry.  Over the past year, in addition to his corporate work, Clive has played a leading role in the UK Vaccine Taskforce which has been recognised as leading one of the most successful rollouts of the COVID-19 vaccination globally.  Clive is an inspiration to us here at C4XD and it is wonderful to see the recognition across the industry for all his contributions to our thriving life sciences sector.”

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (C4XD) aims to create the world’s most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company’s business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD’s commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to:www.c4xdiscovery.com